Correlation of pressure gradient in three hepatic veins with portal pressure gradient.

Free hepatic venous pressure Hepatic venous pressure gradient Portal hypertension Portal pressure gradient

Journal

World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806

Informations de publication

Date de publication:
16 May 2022
Historique:
received: 26 11 2021
revised: 25 01 2022
accepted: 26 03 2022
entrez: 6 6 2022
pubmed: 7 6 2022
medline: 7 6 2022
Statut: ppublish

Résumé

The liver is one of the most important organs in the human body, with functions such as detoxification, digestion, and blood coagulation. In terms of vascular anatomy, the liver is divided into the left and the right liver by the main portal vein, and there are three hepatic efferent veins (right, middle, and left) and two portal branches. Patients with impaired liver function have increased intrahepatic vascular resistance and splanchnic vasodilation, which may lead to an increase in the portal pressure gradient (PPG) and cause portal hypertension (PHT). In order to measure the increased pressure gradient of portal vein, the hepatic venous pressure gradient (HVPG) can be measured to reflect it in clinical practice. The accuracy of PPG measurements is directly related to patient prognosis. To analyze the correlation between HVPG of three hepatic veins and PPG in patients with PHT. From January 2017 to December 2019, 102 patients with PHT who met the inclusion criteria were evaluated during the transjugular intrahepatic portosystemic shunt procedure and analyzed. The mean HVPG of the middle hepatic vein was 17.47 ± 10.25 mmHg, and the mean HVPG of the right and left hepatic veins was 16.34 ± 7.60 and 16.52 ± 8.15 mmHg, respectively. The average PPG was 26.03 ± 9.24 mmHg. The correlation coefficient and coefficient of determination of the right hepatic vein, middle hepatic vein, and left hepatic vein were 0.15 and 0.02 ( Measurement of the middle hepatic vein HVPG could better represent PPG. Considering the high success rate of clinical measurement of the right hepatic vein, it can be the second choice.

Sections du résumé

BACKGROUND BACKGROUND
The liver is one of the most important organs in the human body, with functions such as detoxification, digestion, and blood coagulation. In terms of vascular anatomy, the liver is divided into the left and the right liver by the main portal vein, and there are three hepatic efferent veins (right, middle, and left) and two portal branches. Patients with impaired liver function have increased intrahepatic vascular resistance and splanchnic vasodilation, which may lead to an increase in the portal pressure gradient (PPG) and cause portal hypertension (PHT). In order to measure the increased pressure gradient of portal vein, the hepatic venous pressure gradient (HVPG) can be measured to reflect it in clinical practice. The accuracy of PPG measurements is directly related to patient prognosis.
AIM OBJECTIVE
To analyze the correlation between HVPG of three hepatic veins and PPG in patients with PHT.
METHODS METHODS
From January 2017 to December 2019, 102 patients with PHT who met the inclusion criteria were evaluated during the transjugular intrahepatic portosystemic shunt procedure and analyzed.
RESULTS RESULTS
The mean HVPG of the middle hepatic vein was 17.47 ± 10.25 mmHg, and the mean HVPG of the right and left hepatic veins was 16.34 ± 7.60 and 16.52 ± 8.15 mmHg, respectively. The average PPG was 26.03 ± 9.24 mmHg. The correlation coefficient and coefficient of determination of the right hepatic vein, middle hepatic vein, and left hepatic vein were 0.15 and 0.02 (
CONCLUSION CONCLUSIONS
Measurement of the middle hepatic vein HVPG could better represent PPG. Considering the high success rate of clinical measurement of the right hepatic vein, it can be the second choice.

Identifiants

pubmed: 35663094
doi: 10.12998/wjcc.v10.i14.4460
pmc: PMC9125293
doi:

Types de publication

Journal Article

Langues

eng

Pagination

4460-4469

Informations de copyright

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Références

World J Gastroenterol. 2020 Oct 28;26(40):6111-6140
pubmed: 33177789
Gastroenterology. 1984 Jun;86(6):1400-3
pubmed: 6714569
Dig Liver Dis. 2011 Oct;43(10):762-7
pubmed: 21549649
Dig Dis Sci. 2009 Jun;54(6):1178-83
pubmed: 18975087
Hepatology. 2004 Feb;39(2):280-2
pubmed: 14767976
Gastrointest Endosc. 2021 Mar;93(3):565-572
pubmed: 32615178
Br J Surg. 2012 Jun;99(6):863
pubmed: 22539122
Zhonghua Gan Zang Bing Za Zhi. 2018 Nov 20;26(11):801-812
pubmed: 30616313
Liver Int. 2014 Jan;34(1):16-25
pubmed: 23763484
Dig Dis Sci. 1999 Jan;44(1):155-62
pubmed: 9952237
Clin Res Hepatol Gastroenterol. 2014 Oct;38(5):564-9
pubmed: 24581591
Br J Surg. 2012 Sep;99(9):1284-9
pubmed: 22864890
Gastroenterology. 2007 Aug;133(2):481-8
pubmed: 17681169
Hepatology. 1985 May-Jun;5(3):415-8
pubmed: 3997071
Dig Dis Sci. 2008 Jan;53(1):7-13
pubmed: 18058232
Hepatology. 1999 Dec;30(6):1393-7
pubmed: 10573517
Semin Liver Dis. 2006 Nov;26(4):348-62
pubmed: 17051449
J Clin Gastroenterol. 2012 Nov-Dec;46(10):880-6
pubmed: 22810110
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
Scand J Gastroenterol. 2013 Apr;48(4):487-95
pubmed: 22871085
J Hepatol. 2009 May;50(5):923-8
pubmed: 19303163

Auteurs

Hao-Yu Wang (HY)

Department of Oncology, The 9Clinical Medical College & Beijing Shijitan Hospital, Peking University, Beijing 100038, China.

Qing-Kun Song (QK)

Division of Clinical Epidemiology and Evidence-Based Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Zhen-Dong Yue (ZD)

Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Lei Wang (L)

Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Zhen-Hua Fan (ZH)

Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Yi-Fan Wu (YF)

Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Cheng-Bin Dong (CB)

Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Yu Zhang (Y)

Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Ming-Ming Meng (MM)

Department of Gastroenterology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.

Ke Zhang (K)

Department of General Surgery, Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.

Li Jiang (L)

Department of General Surgery, Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China.

Hui-Guo Ding (HG)

Department of Gastroenterology and Hepatology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.

Yue-Ning Zhang (YN)

Department of Gastroenterology and Hepatology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.

Yong-Ping Yang (YP)

Department of Therapeutic Research for Liver Cancer, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.

Fu-Quan Liu (FQ)

Department of Oncology, The 9 Clinical Medical College & Beijing Shijitan Hospital, Peking University, Beijing 100038, China. lfuquan@aliyun.com.

Classifications MeSH